Novel Therapeutics:
Electrolyte Therapeutics Platform: Restoring Mineral Balance to Protect the Heart and Kidneys
Dr. Orson W. Moe, M.D.
- Professor of Internal Medicine (Nephrology) and Physiology, UT Southwestern
Dr. Charles Y. Pak, M.D.
- Professor Emeritus of Internal Medicine (Mineral Metabolism), UT Southwestern
Chronic kidney disease and hypertension affect hundreds of millions worldwide, yet few safe oral therapies exist to correct the underlying mineral and electrolyte imbalances that drive cardiovascular damage. Drs. Moe and Pak have developed two proprietary oral formulations—Ca-Mg-Citrate and K-Mg-Citrate—that safely rebalance calcium, magnesium, and potassium to improve vascular function and reduce cardiac risk. Early clinical trials have already shown reduced cardiovascular events and meaningful blood-pressure improvements. Unlike binding resins or biologics, these electrolyte-based therapeutics act physiologically, offering a scalable, low-cost solution with clear regulatory and market pathways. Their approach positions UTSW to lead a new class of cardio-renal metabolic therapies—and creates a natural collaboration opportunity with AstraZeneca’s growing CVRM and Lokelma portfolio in Dallas.
